Atyr Pharma Inc (ATYR)
$2.22
Performance
- $2.18$2.31$2.22
1.8%
Downside
Day's Volatility :5.63%
Upside
3.9%
- $1.08$2.50$2.22
51.35%
Downside
52 Weeks Volatility :56.8%
Upside
11.2%
Returns
| Period | Atyr Pharma Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 22.53% | 0.0% |
6 Months | 22.53% | 0.0% |
1 Year | 22.53% | 0.0% |
3 Years | 22.53% | -20.2% |
Highlights
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | 0.0% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | 0.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
Analyst Recommendation
Technicals Summary
Sell
Neutral
Buy
Atyr Pharma Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Atyr Pharma Inc | 45.75% | 22.53% | 22.53% | 22.53% | 22.53% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Atyr Pharma Inc | NA | NA | NA | 0.0 | 0.0 | 0.0 | NA | NA |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Atyr Pharma Inc | NA | $133.2M | 22.53% | NA | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Company Information
atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation
Organization | Atyr Pharma Inc |
Employees | 56 |
CEO | Sanjay Shukla |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$2.22
-0.45%
Keyarch Acquisition Corp
$2.22
-0.45%
Connexa Sports Technologies Inc
$2.22
-0.45%
Us Value Etf
$2.22
-0.45%
First Wave Biopharma Inc
$2.22
-0.45%
Global X Msci Next Emerging
$2.22
-0.45%
Fat Projects Acquisition Corp
$2.22
-0.45%
Capital Link Global Fintech
$2.22
-0.45%
Applied Uv Inc
$2.22
-0.45%